US Bancorp DE Has $30,000 Stake in Pacira BioSciences, Inc. (NASDAQ:PCRX)

US Bancorp DE reduced its holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX) by 81.1% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,967 shares of the company’s stock after selling 8,442 shares during the period. US Bancorp DE’s holdings in Pacira BioSciences were worth $30,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Pacer Advisors Inc. grew its holdings in shares of Pacira BioSciences by 37.5% during the second quarter. Pacer Advisors Inc. now owns 2,162,787 shares of the company’s stock worth $61,877,000 after buying an additional 590,082 shares in the last quarter. Archon Capital Management LLC bought a new position in shares of Pacira BioSciences during the first quarter worth approximately $15,677,000. Fort Washington Investment Advisors Inc. OH acquired a new stake in Pacira BioSciences during the second quarter worth about $13,240,000. Assenagon Asset Management S.A. raised its holdings in shares of Pacira BioSciences by 314.4% during the 3rd quarter. Assenagon Asset Management S.A. now owns 553,114 shares of the company’s stock worth $8,324,000 after buying an additional 419,656 shares in the last quarter. Finally, Doma Perpetual Capital Management LLC increased its holdings in shares of Pacira BioSciences by 71.8% during the second quarter. Doma Perpetual Capital Management LLC now owns 1,000,761 shares of the company’s stock worth $28,632,000 after buying an additional 418,321 shares in the last quarter. 99.73% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

PCRX has been the subject of a number of research analyst reports. Raymond James downgraded Pacira BioSciences from an “outperform” rating to a “market perform” rating in a report on Monday, August 12th. Royal Bank of Canada upped their target price on Pacira BioSciences from $15.00 to $16.00 and gave the company a “sector perform” rating in a report on Thursday, November 7th. Barclays lowered their price target on shares of Pacira BioSciences from $25.00 to $17.00 and set an “equal weight” rating on the stock in a report on Tuesday, November 12th. Piper Sandler downgraded Pacira BioSciences from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Finally, Jefferies Financial Group boosted their price objective on Pacira BioSciences from $15.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $23.50.

Pacira BioSciences Stock Up 0.2 %

Shares of NASDAQ:PCRX opened at $16.64 on Tuesday. The firm has a market capitalization of $768.32 million, a PE ratio of -8.18 and a beta of 0.82. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.89 and a current ratio of 2.25. Pacira BioSciences, Inc. has a 52-week low of $11.16 and a 52-week high of $35.95. The firm has a fifty day moving average of $15.81 and a 200 day moving average of $20.60.

Pacira BioSciences Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.